AI drug pioneer Recursion Pharmaceuticals (NASDAQ:RXRX) said Wednesday that one of its experimental treatments hit a key milestone.
Recursion was able to use its artificial intelligence-enabled drug discovery platform to identify an area of biology to target for the treatment of solid tumors and lymphoma, match it with a drug candidate and move all the way to gaining regulatory approval to begin studies in less than 18 months.
“We think that’s a really exciting proof point, not only for us as a company, but I think for the techbio industry as well,” said CEO and co-founder Chris Gibson.
The Food and Drug Administration cleared the investigational new drug application for a phase 1/2 clinical trial of an experimental drug candidate known as REC-1245. The company said the potential market for this treatment could be more than 100,000 patients in the U.S. and European Union.
The trial will evaluate the safety and tolerability of REC-1245 and will begin in the fourth quarter of this year. The phase 1 data from the dose-escalation portion of the study could be completed by the end of next year, the company has said.
The drug will target RBM39, which Recursion said appears functionally similar to a well-known but hard to target marker known as CDK12 to treat advanced HR-proficient cancers such as ovarian, prostate, breast and pancreatic cancers.
RXRX shares acquired a dime, or 1.6%, to $6.27.
Related Stories
